VRNA - Verona Pharma plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

Currency in GBP. All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
-
0
0
0
0
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
33,460
19,294
23,717
4,522
7,265
Selling General and Administrative
3,955
2,669
2,840
1,312
915
Total Operating Expenses
41,052
25,600
29,720
6,878
8,971
Operating Income or Loss
-41,052
-25,600
-29,720
-6,878
-8,971
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-
-
-
1,755
0
Income Before Tax
-34,771
-24,133
-25,203
-5,973
-8,926
Income Tax Expense
-7,298
-4,232
-4,706
-954
-1,509
Income from Continuing Operations
-27,473
-19,901
-20,497
-5,018
-7,417
Net Income
-27,473
-19,901
-20,497
-5,018
-7,417
Net Income available to common shareholders
-27,473
-19,901
-20,497
-5,018
-7,417
Reported EPS
Basic
-
-1.51
-1.87
-1.20
-2.92
Diluted
-
-1.51
-1.87
-1.20
-2.92
Weighted average shares outstanding
Basic
-
13,139
10,969
4,187
2,525
Diluted
-
13,139
10,969
4,187
2,525
EBITDA
-
-25,502
-29,597
-6,817
-8,918